Development of tubulin polymerization inhibitors as anticancer agents

Peerzada, Mudasir Nabi; Dar, Mohammad Sultan; Verma, Saurabh

doi:10.1080/13543776.2023.2291390

Cited by 8 publications

(3 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 Therefore, several tubulin polymerization inhibitors have been developed. 39 Since we developed our quinoline derivatives to act as tubulin polymerization inhibitors, their ability to induce cell cycle arrest at G2 and M phases was evaluated. Hence, we focused on elucidating the cellular mechanisms underlying its potent cytotoxic activity against MDA-MB-231.…”

Section: Cell Cycle Analysis By Ow Cytometrymentioning

confidence: 99%

Exploring the antitumor potential of novel quinoline derivatives via tubulin polymerization inhibition in breast cancer; design, synthesis and molecular docking

Abdelmegeed,

Abdel Ghany,

Youssef

et al. 2024

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Cell Cycle Analysis By Ow Cytometrymentioning

confidence: 99%

Exploring the antitumor potential of novel quinoline derivatives via tubulin polymerization inhibition in breast cancer; design, synthesis and molecular docking

Abdelmegeed,

Abdel Ghany,

Youssef

et al. 2024

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…While other tubulin inhibitors, such as derivatives of taxol, vincristine, and colchicine, have been explored in ADCs, their efficacy has been limited. 40 , 41 The third category comprises alkylating agents, like duocarmazine.…”

Section: Mechanistic Insights Into Adcs In Targeted Cancer Therapymentioning

confidence: 99%

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

He,

Zeng,

Wang

et al. 2024

MedComm

View full text Add to dashboard Cite

Antibody–drug conjugates (ADCs) consist of monoclonal antibodies that target tumor cells and cytotoxic drugs linked through linkers. By leveraging antibodies’ targeting properties, ADCs deliver cytotoxic drugs into tumor cells via endocytosis after identifying the tumor antigen. This precise method aims to kill tumor cells selectively while minimizing harm to normal cells, offering safe and effective therapeutic benefits. Recent years have seen significant progress in antitumor treatment with ADC development, providing patients with new and potent treatment options. With over 300 ADCs explored for various tumor indications and some already approved for clinical use, challenges such as resistance due to factors like antigen expression, ADC processing, and payload have emerged. This review aims to outline the history of ADC development, their structure, mechanism of action, recent composition advancements, target selection, completed and ongoing clinical trials, resistance mechanisms, and intervention strategies. Additionally, it will delve into the potential of ADCs with novel markers, linkers, payloads, and innovative action mechanisms to enhance cancer treatment options. The evolution of ADCs has also led to the emergence of combination therapy as a new therapeutic approach to improve drug efficacy.

show abstract

“…9–11 The clinical success of such agents demonstrates that enormous potential of this target to the design and development of new anti-tubulin polymerization compounds as effective targeted anticancer regimens. 12…”

Section: Introductionmentioning

confidence: 99%